Wall Street brokerages expect Abeona Therapeutics Inc. (NASDAQ:ABEO) to report ($0.12) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have issued estimates for Abeona Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.13) and the highest estimate coming in at ($0.12). Abeona Therapeutics reported earnings of ($0.20) per share during the same quarter last year, which indicates a positive year over year growth rate of 40%. The firm is expected to report its next earnings results on Tuesday, August 15th.
On average, analysts expect that Abeona Therapeutics will report full year earnings of ($0.53) per share for the current fiscal year, with EPS estimates ranging from ($0.62) to ($0.44). For the next year, analysts expect that the firm will post earnings of ($0.23) per share, with EPS estimates ranging from ($0.76) to $0.86. Zacks’ EPS calculations are an average based on a survey of research analysts that that provide coverage for Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Thursday, May 18th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.28 million. Abeona Therapeutics had a negative net margin of 2,568.57% and a negative return on equity of 26.99%.
A number of brokerages recently commented on ABEO. FBR & Co reiterated a “buy” rating on shares of Abeona Therapeutics in a research note on Friday, May 26th. Maxim Group set a $14.00 price target on shares of Abeona Therapeutics and gave the company a “buy” rating in a research note on Saturday, May 13th. Cantor Fitzgerald reissued a “buy” rating and issued a $21.00 price objective on shares of Abeona Therapeutics in a report on Tuesday, June 6th. HC Wainwright set a $20.00 price objective on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Wednesday, July 19th. Finally, Zacks Investment Research raised shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Tuesday, July 11th. Eight research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of $17.86.
A number of hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its stake in Abeona Therapeutics by 869.7% in the first quarter. Goldman Sachs Group Inc. now owns 116,000 shares of the biopharmaceutical company’s stock worth $580,000 after buying an additional 104,038 shares in the last quarter. Family Management Corp acquired a new stake in Abeona Therapeutics during the first quarter worth about $120,000. Highbridge Capital Management LLC increased its stake in Abeona Therapeutics by 23.5% in the first quarter. Highbridge Capital Management LLC now owns 681,611 shares of the biopharmaceutical company’s stock worth $3,408,000 after buying an additional 129,811 shares in the last quarter. Geode Capital Management LLC increased its stake in Abeona Therapeutics by 2.4% in the first quarter. Geode Capital Management LLC now owns 196,073 shares of the biopharmaceutical company’s stock worth $980,000 after buying an additional 4,588 shares in the last quarter. Finally, Segantii Capital Management Ltd increased its stake in Abeona Therapeutics by 564.6% in the first quarter. Segantii Capital Management Ltd now owns 33,894 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 28,794 shares in the last quarter. 35.64% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This news story was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/07/27/abeona-therapeutics-inc-abeo-expected-to-post-earnings-of-0-12-per-share.html.
Shares of Abeona Therapeutics (NASDAQ:ABEO) traded down 3.45% on Monday, reaching $8.40. 591,333 shares of the company’s stock were exchanged. The firm’s 50-day moving average price is $7.04 and its 200 day moving average price is $5.74. The company’s market cap is $338.14 million. Abeona Therapeutics has a 12 month low of $2.50 and a 12 month high of $10.26.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
